OLIGOFASTX consortium shares at Farmaforum the progress of the project after 1 year of work
They have organized the round table "End-to-end technological solution for the development of oligonucleotide-based therapies"
One year after the start of the Oligofastx project funded by CDTI in the Missions 2021 call, the partner companies have shared in Farmaforum the collaborative work carried out for the development of oligonucleotide-based therapies.
The round table was moderated by the scientific coordinator of the project and R&D manager of Sylentis - Tamara Martinez and was attended by Javier Iglesias - R&D Director of Nostrum Biodiscovery, Francisco Manuel Reyes - Business Development Manager of 53Biologics, Rebeca Alonso - CSO of Nanovex Biotechnologies and David Piñeiro - Project Manager of aptaTargets.
After a global explanation of the project, the rare diseases and the technologies used, they presented the novel approaches that are being carried out for the generation in Spain of a biopharmaceutical industrial fabric specialized in the development of oligonucleotide-based therapies (the companies Arthex Biotech and Aptus Biotech are also part of the consortium).
In the context of the particular problems in each case, the research effort carried out in the project together with collaborating public organizations for the design and modeling of molecules using Artificial Intelligence, the nanoliberation of drugs and alternative synthesis processes, which enrich the process of developing oligonucleotide RNA-based therapies against the 7 rare diseases treated in Oligofastx.
In the coming days we will share in video format the interventions of the speakers in our social networks: LinkedIn, Twitter and Youtube. follow us!
For more information:
For more information, visit our website: www.oligofastx.com and our social networks LinkedIn, Twitter and YouTube.